{"id":6659,"date":"2025-09-07T23:02:32","date_gmt":"2025-09-07T23:02:32","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/09\/07\/summit-therapeutics-lung-cancer-ivonescimab\/"},"modified":"2025-09-07T23:02:32","modified_gmt":"2025-09-07T23:02:32","slug":"summit-therapeutics-lung-cancer-ivonescimab","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/09\/07\/summit-therapeutics-lung-cancer-ivonescimab\/","title":{"rendered":"STAT+: Summit Therapeutics hits possible snag on lung cancer drug seen as a blockbuster"},"content":{"rendered":"<p>    STAT+: Summit Therapeutics hits possible snag on lung cancer drug seen as a blockbuster<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>Summit Therapeutics may have a geography problem with its lung cancer drug ivonescimab.<\/p>\n<p>In a study update reported Sunday, patients from North America and Europe treated with the drug saw their lung cancer return and progress faster than patients from China \u2014 a discordant result that could complicate Summit\u2019s plans to secure approval of ivonescimab in the U.S. and Europe.<\/p>\n<p>The risk of tumor progression fell by 45% for participants from China treated with ivonescimab and chemotherapy compared to chemotherapy and a placebo. For participants from Western countries, however, the risk of tumor progression was reduced by 33% \u2014 an outcome that failed to reach statistical significance.\u00a0<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/09\/07\/summit-therapeutics-lung-cancer-ivonescimab\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Adam Feuerstein<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/09\/07\/summit-therapeutics-lung-cancer-ivonescimab\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Summit Therapeutics hits possible snag on lung cancer drug seen as a blockbuster Summit Therapeutics may have a geography problem with its lung cancer drug ivonescimab. In a study update reported Sunday, patients from North America and Europe treated with the drug saw their lung cancer return and progress faster than patients from China [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,2159,2208,2155,2152],"tags":[2150],"class_list":["post-6659","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-cancer","category-drug-development","category-pharmaceuticals","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/6659"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=6659"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/6659\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=6659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=6659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=6659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}